AB Science SA · EURONEXT:AB
AB Science SA — Corporate Update (May 2020)
23 slides from AB Science SA's corporate update, May 11, 2020
Slide 1: AB Science Webconference: Masitinib + Isoquercetin in COVID-19
AB SCIENCE WEBCONFERENCE MASITINIB + ISOQUERCETIN IN COVID-19 11 May 2020
Slide 2: Disclaimer
Disclaimer This presentation, together with the material set forth herein, does not constitute an offer of securities for sale nor the solicitation of an offer to purchase securities in any jurisdiction. Distribution of such presentation in certain jurisdiction may constitute a breach of applicable
Slide 3: Speakers
Speakers Alain MOUSSY, MBA Co-founder and Chief Executive Officer. Jean-Pierre KINET, MD, PhD Co-founder and Co-President of Scientific Committee Professor of Pathology at Harvard Medical School (Boston – USA) 3
Slide 4: Agenda
AGENDA 1. Scientific rationale for combining masitinib and IsoQ in Covid-19 2. Positioning and Key differentiating factors 3. Study Design
Slide 5: 1. Scientific rationale for combining masitinib and IsoQ in Covid-19
1. Scientific rationale for combining masitinib and IsoQ in Covid-19
Slide 6: COVID-19 cytokine storm and severe pulmonary inflammation
Scientific Rationale In moderate and severe forms of the disease, Covid-19 is triggering a “cytokine storm” leading to severe pulmonary inflammation and thrombosis associated with acute respiratory distress syndrome (ARDS) and potentially death. ❖ COVID-19 infection causes clusters of severe respira
Slide 7: Scientific Rationale: Mast cells activity inhibition
Scientific Rationale Inflammatory responses and cytokine storm Cytokine Storm Syndrome may be avoided by Mast cells activity inhibition ▪ Mast cells contribute to COVID19-induced ▪ Masitinib inhibits c-Kit (IC50=100-300nM). c-Kit is highly expressed inflammation by activating the early release of in
Slide 8: Scientific Rationale: Macrophage activity inhibition
Scientific Rationale Cytokine Storm Syndrome may be avoided by Macrophage activity inhibition ▪ There is evidence for Macrophage Activation ▪ Masitinib inhibits macrophage colony-stimulating factor 1 Syndrome emerging in the COVID-19 setting receptor MCSF1R with an IC50=90nM. that is supported by th
Slide 9: Scientific Rationale: Preventing lung injuries
Scientific Rationale Masitinib may prevent lung injuries by decreasing mast cells and macrophages lung infiltration ▪ Lung injuries in COVID-19 are life-threatening ▪ Masitinib showed prevention against acute chest syndrome symptoms in an animal model of sickle cell disease (SCD). Masitinib prevente
Slide 10: Scientific Rationale: Neutrophils inhibition with Isoquercetin
Scientific Rationale Cytokine Storm Syndrome may be avoided by Neutrophils inhibition with Isoquercetin ▪ Neutrophilia predicts poor outcomes in patients ▪ Quercetin reduces neutrophil (Souto FO, 2011) with COVID-19 (Wang, 2020) ▪ Neutrophil-to-Lymphocyte ratio is a marker of ▪ Quercetin diminish ne
Slide 11: Scientific Rationale: Decreasing D-Dimer by Isoquercetin
Scientific Rationale Decreasing D-Dimer by Isoquercetin may prevent death and injuries due to thrombosis ▪ Increase in D-dimer is a predictor of in-hospital ▪ Isoquercetin has been shown recently in a phase II clinical mortality in patients with Covid-19 (Wu C 2020; Gao trial decreased D-Dimer by in
Slide 12: Scientific Rationale: Treating aged people
Scientific Rationale Masitinib and Isoquercetin is suited to treat aged people which are the most exposed to death. ▪ Deadly pulmonary inflammation occurs more ▪ In a model of Amyotrophic Lateral Sclerosis (Maladie de frequently in aged people. Charcot), Masitinib and Isoquercetin kills senescent ce
Slide 13: Scientific Rationale: Neurological symptoms in COVID-19
Scientific Rationale Severe and persistent neurological symptoms are the new challenge in COVID-19 and Masitinib could control them. ▪ Covid19 virus infect nervous system and ▪ Masitinib inhibits proliferation and migration of microglia by skeletal muscle as well as the respiratory tract. targeting
Slide 14: Scientific Rationale: Isoquercetin anti-viral activity
Scientific Rationale Isoquercetin has an anti-viral activity in-vitro and may have activity against COVID-19 virus in human ▪ Isoquercetin has a broad antiviral spectrum. It inhibits Hepatitis C Virus, Human Respiratory Syncytial Virus, Influenza A virus, Dengue virus, Enterovirus 71, Rhinovirus cel
Slide 15: Safety profiles of Masitinib and IsoQuercetin
Scientific Rationale The safety profiles of Masitinib and IsoQuercetin are well defined. ❖ Masitinib ▪ Over 7500 patients randomized ▪ Evaluated in patients wit various diseases, age and comorbidities (Alzheimer, Multiple sclerosis, Amyotrophic lateral sclerosis, Asthma, Mastocytosis ▪ Safety recogn
Slide 16: 2. Positioning and Key differentiating factors
2. Positioning and Key differentiating factors
Slide 17: Overview of strategies pursued
Overview of strategies pursued The combination Masitinib + IsoQuercetin is one of the treatment candidates in the immunomodulation strategy. Strategy Severity Target Agent Company Inhibiting glycosylation of host receptors Hydroxychloroquine generic 3CL protease Lopinavir/Ritonavir generic Mild S pr
Slide 18: Positioning
Positioning Masitinib combined with Isoquercetin is positioned in moderate and severe form of COVID-19. Disease severity Signs and symptoms Scope % Mild No supplemental oxygen therapy requirement or evidence of pneumonia No 81% Meeting of the following criteria: • Showing fever and respiratory sympt
Slide 19: Key Differentiating Factors
Key Differentiating Factors The combination Masitinib + IsoQuercetin differentiates from other strategies on key points. ❖ Targets the innate immune system cells upstream rather than the released interleukins downstream ❖ Can potentially prevent thrombosis (ICU and death) ❖ Can potentially treat the
Slide 20: 3. Study Design
3. Study Design
Slide 21: AB20001 Phase 2 study design
AB20001 Phase 2 study design Study AB20001 will enroll 200 patients with moderate and severe forms of the disease without limitation of age (i.e. patients above 80 will be enrolled). ❖ Randomized, Open-label, Multicentre, Comparative Phase 2 study ❖ Main Inclusion Criteria ▪ Moderate cases o Showing
Slide 22: AB20001 study design: endpoints
AB20001 Phase 2 study design Study AB20001 will assess efficacy, safety, and PK parameters of the combination masitinib + Isoquerceting ❖ Primary endpoint : ▪ Clinical status of patients at day15 using the 7-point ordinal scale The 7-point ordinal scale for clinical status is: 1. Not hospitalized, n
Slide 23: AB20001 coordinating investigator and study timelines
AB20001 Phase 2 study design Study AB20001 plans to enroll patients in France and potentially in other countries and will last 2 to 6 months depending on intensity and number of waive of contaminations. ❖ Coordinating investigator ▪ Pascal Chanez ▪ Hôpital Nord, AP-HM, Marseille - France ❖ Study tim